Erik Nutma

173 Astrocyte and Oligodendrocyte Crosstalk from amyloid-beta-induced neurotoxicity: relevance to Alzheimer’s disease. Biochem Biophys Res Commun. Sep 9 2011;412(4):565-71. doi:10.1016/j.bbrc.2011.07.127 86. Hsu MP, et al. Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M. Glia. Jan 2015;63(1):132-41. doi:10.1002/glia.22739 87. Omari KM, et al. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia. Jan 1 2006;53(1):24-31. doi:10.1002/glia.20246 88. Tzartos JS, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. Jan 2008;172(1):146-55. doi:10.2353/ ajpath.2008.070690 89. Choi SS, et al. Human astrocytes: secretome profiles of cytokines and chemokines. PLOS ONE. 2014/04/01 2014;9(4):e92325. doi:10.1371/ journal.pone.0092325 90. Moynagh PN. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat. Sep 2005;207(3):265-9. doi:10.1111/j.1469-7580.2005.00445.x 91. Moyon S, et al. Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. J Neurosci. Jan 7 2015;35(1):4-20. doi:10.1523/ JNEUROSCI.0849-14.2015 92. Kim WK, et al. Secretome analysis of human oligodendrocytes derived from neural stem cells. PLOS ONE. 2014/01/02 2014;9(1):e84292. doi:10.1371/journal.pone.0084292 93. Kadi L, et al. Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro. J Neuroimmunol. May 2006;174(1-2):133-46. doi:10.1016/j. jneuroim.2006.01.011 94. Zhang ZJ, et al. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain. Oct 2013;154(10):2185-2197. doi:10.1016/j. pain.2013.07.002 95. Chang R, et al. Tumor necrosis factor alpha Inhibition for Alzheimer’s Disease. J Cent Nerv Syst Dis. 2017/01 2017;9:1179573517709278. doi:10.1177/1179573517709278 96. Fischer R, et al. Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia. Feb 2014;62(2):272-83. doi:10.1002/glia.22605 97. Hofman FM, et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. Aug 1 1989;170(2):607-12. doi:10.1084/jem.170.2.607 98. Selmaj K, et al. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol. Sep 1 1991;147(5):15229. 99. SelmajK,etal.Tumornecrosisfactormediatesmyelin damage in organotypic cultures of nervous tissue. Ann N Y Acad Sci. 1988/11 1988;540(1 Advances in N):568-70. doi:10.1111/j.1749-6632.1988. tb27175.x 100. Deng Y, et al. Astrocyte-derived proinflammatory cytokines induce hypomyelination in the periventricular whitematter in the hypoxic neonatal brain. PLOS ONE. 2014/01/31 2014;9(1):e87420. doi:10.1371/journal.pone.0087420 101. Agresti C, et al. Reversible inhibitory effects of interferon-gamma and tumour necrosis factoralpha on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur J Neurosci. Jun 1996;8(6):1106-16. doi:10.1111/j.1460-9568.1996. tb01278.x 102. Hindinger C, et al. IFN-gamma signaling to astrocytes protects from autoimmune mediated neurological disability. PLOS ONE. 2012/07/27 2012;7(7):e42088. doi:10.1371/journal. pone.0042088 103. LaFerla FM, et al. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma. J Mol Neurosci. Aug 2000;15(1):45-59. doi:10.1385/JMN:15:1:45 104. Panitch HS, et al. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. Jul 1987;37(7):1097-102. doi:10.1212/ wnl.37.7.1097 105. Butt AM, et al. Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo. Exp Neurol. Mar 2005;192(1):125-33. doi:10.1016/j.expneurol.2004.11.007 106. Gross RE, et al. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron. Oct 1996;17(4):595-606. doi:10.1016/ s0896-6273(00)80193-2 107. Hesp ZC, et al. Chronic oligodendrogenesis and remyelination after spinal cord injury in mice and rats. J Neurosci. Jan 21 2015;35(3):1274-90. doi:10.1523/JNEUROSCI.2568-14.2015 108. Clarner T, et al. Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. J Neuroendocrinol. Jul 2011;23(7):601-11. doi:10.1111/j.1365-2826.2011.02140.x 109.McMorris FA, et al. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci U S A. Feb 1986;83(3):822-6. doi:10.1073/ pnas.83.3.822 110. Balabanov R, et al. Interferon-gammaoligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci. Feb 21 2007;27(8):2013-24. doi:10.1523/ JNEUROSCI.4689-06.2007 111. Semple BD, et al. CCL2 modulates cytokine production in cultured mouse astrocytes. J

RkJQdWJsaXNoZXIy MTk4NDMw